性结肠炎儿童的提奥普林维护疗法:一个多中心回顾性研究
Firas Abu Hanna1, Ohad Atia2, Anat Yerushalmy Feler3
1From the Pediatric Gastroenterology Unit, Emek Medical Centre, Afula, Israel.
Journal of pediatric gastroenterology and nutrition
|July 26, 2023
概括
提奥普林在一年内有效诱导超过一半的儿科性结肠炎患者的无皮质类固醇缓解. 这项研究表明,在考虑为患有UC的儿童服用生物药物之前,氨酸可以是一个有价值的治疗选择.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 免疫调节疗法 免疫调节疗法
背景情况:
- 儿童性结肠炎 (UC) 需要有效的治疗.
- 提奥普林用于儿科UC,但安全性和疗效数据有限.
研究的目的:
- 为了评估小儿UC患者的蒂奥普林治疗的短期和长期结果.
- 为了确定无皮质固醇缓解的速度和需要救援治疗.
主要方法:
- 对133名患有UC的儿童 (2-18岁) 进行了回顾性审查,这些儿童接受了氨酸治疗.
- 主要结局:在52周没有救援治疗 (infliximab,氨酸抑制剂或切除术) 的情况下,无皮质类固醇的临床缓解.
主要成果:
- 56%的患者在没有救援治疗的情况下在52周内实现了无皮质类固醇缓解.
- 长期维持缓解救援治疗后的缓解观察到83%的人在1年后,在4年后降至37%.
- 在这个队列中没有确定缓解的预测因素.
结论:
- 提奥普林在儿童UC患者的临床缓解中表现出有效性.
- 这些发现支持在儿科UC治疗中考虑提奥普林作为生物治疗前的治疗选择.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
356
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
356
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
560
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
560
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153


